Related Experiment Video
Updated: Jun 4, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Association of SGLT2 Inhibitor Initiation and PSA Response in Prostate Cancer
Etan R Aber1, Michael A Carducci2, Channing J Paller2
1Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Introduction:
Non-castrating therapies are an unmet clinical need for patients with advanced prostate cancer. To maximize quality of life and prioritize cardiovascular health, we investigated SGLT2 inhibitors as a non-castrating therapy in patients with prostate cancer.
Materials And Methods:
We conducted a retrospective analysis of patients with either local or biochemically recurrent prostate cancer who initiated therapy with an SGLT2 inhibitor without concurrent androgen deprivation therapy. The primary endpoint was an estimated PSA50 response rate. A secondary endpoint was PSA any response rate.
Results:
A total of nine patients (median age 63 years old; 44.4% Black; median PSA 3.7; 33.3% localized, 66.7% biochemically recurrent) were included. The PSA50 and PSAany response rate were 22.2% (N = 2/9) and 44.4% (N = 4/9), respectively.
Conclusions:
Patients with localized or biochemically recurrent prostate cancer achieved PSA responses to SGLT2 inhibitors. These findings justify prospective studies in patients with prostate cancer.
Insights
Sodium-glucose cotransporter 2 (SGLT2) inhibitors showed promise as a non-castrating therapy for prostate cancer, with some patients achieving prostate-specific antigen (PSA) responses. Further research is warranted to confirm these findings.
Area of Science:
- Oncology
- Endocrinology
- Cardiovascular Medicine
Background:
- Advanced prostate cancer necessitates non-castrating therapies to preserve quality of life and cardiovascular health.
- SGLT2 inhibitors are explored as a novel therapeutic option.
- Current treatment landscape lacks sufficient non-hormonal options for prostate cancer management.
Purpose of the Study:
- To investigate the efficacy of SGLT2 inhibitors as a non-castrating therapy in patients with prostate cancer.
- To assess the impact of SGLT2 inhibitors on prostate-specific antigen (PSA) levels.
- To evaluate SGLT2 inhibitors in patients with localized or biochemically recurrent prostate cancer.
Main Methods:
- Retrospective analysis of nine patients with prostate cancer receiving SGLT2 inhibitors.
- Patients had either localized or biochemically recurrent disease.
- Exclusion of concurrent androgen deprivation therapy; primary endpoint was PSA50 response rate.
Main Results:
- Two out of nine patients (22.2%) achieved a PSA50 response.
- Four out of nine patients (44.4%) demonstrated any PSA response.
- Median patient age was 63; 44.4% were Black; median PSA was 3.7.
Conclusions:
- SGLT2 inhibitors demonstrated a potential to induce PSA responses in patients with localized or biochemically recurrent prostate cancer.
- These preliminary findings support the need for prospective clinical trials.
- SGLT2 inhibitors may represent a viable non-castrating treatment strategy for select prostate cancer patients.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:23Dipeptidyl Peptidase 4 Inhibitors